Sort by

Send to

Choose Destination

Search results

Items: 5


mTOR co-targeting strategies for head and neck cancer therapy.

Wang Z, Valera JC, Zhao X, Chen Q, Silvio Gutkind J.

Cancer Metastasis Rev. 2017 Sep;36(3):491-502. doi: 10.1007/s10555-017-9688-7. Review. Erratum in: Cancer Metastasis Rev. 2018 Sep 5;:.


SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification.

Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J, Curti C.

Oral Oncol. 2012 Nov;48(11):1106-13. doi: 10.1016/j.oraloncology.2012.05.014. Epub 2012 Jun 26.


Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome.

Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, Prime SS, Teo SH, Silvio Gutkind J, Patel V, Cheong SC.

Cancer Lett. 2012 Aug 1;321(1):18-26. doi: 10.1016/j.canlet.2012.03.025. Epub 2012 Mar 27.


c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.

Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramírez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Ramón y Cajal S, Silvio Gutkind J, Sánchez-Prieto R.

Int J Cancer. 2008 Jan 15;122(2):289-97.


Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma.

Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN.

Oral Oncol. 2007 May;43(5):440-54. Epub 2006 Sep 15.


Supplemental Content

Loading ...
Support Center